<DOC>
	<DOCNO>NCT01276223</DOCNO>
	<brief_summary>The purpose study determine difluprednate ophthalmic emulsion effective reduce ocular symptom dry eye disease , measure global Visual Analog Scale ( VAS ) discomfort score .</brief_summary>
	<brief_title>Evaluation Anti-Inflammatory Treatment Dry Eye Patients</brief_title>
	<detailed_description>Following Run-In , patient qualify treatment randomize 1:1 receive Durezol ( experimental group ) Vehicle ( control group ) 5 week .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Fluprednisolone</mesh_term>
	<mesh_term>Difluprednate</mesh_term>
	<criteria>Normal subject : No known history dry eye disease . Noncontact lens wearer . No current use artificial tear dry eye treatment . OR Dry eye patient : At least 6 month history dry eye . Noncontact lens wearer . Uses artificial tear . Experiences persistent ocular discomfort . Other protocoldefined inclusion criterion may apply . The presence acute infectious noninfectious ocular condition either eye within 1 month Visit 1 . Severe Sjogren 's Syndrome . Lid function abnormality . Use steroid , tetracycline , doxycycline , etc. , within 30 day Visit 1 . History corneal surgery include refractive surgery . History glaucoma ocular hypertension Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Dry eye</keyword>
	<keyword>ocular discomfort</keyword>
</DOC>